| Dr Peter Anthony Ricketti, DO | |
|
1544 Kuser Rd Ste C6, Trenton, NJ 08619-3830 | |
| (609) 581-9900 | |
| (609) 581-9905 |
| Full Name | Dr Peter Anthony Ricketti |
|---|---|
| Gender | Male |
| Speciality | Allergy/immunology |
| Experience | 12 Years |
| Location | 1544 Kuser Rd Ste C6, Trenton, New Jersey |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1013283233 | NPI | - | NPPES |
| Facility Name | Location | Facility Type |
|---|---|---|
| Capital Health Medical Center - Hopewell | Pennington, NJ | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Mercer Allergy And Pulmonary Associates Llc | 9436376605 | 2 |
News Archive
Connecticut: The Associated Press/Hartford Courant reports, "Gov. M. Jodi Rell has vetoed two health insurance bills he said were "well-intentioned" but "would cost the state billions of dollars before any economic recovery is complete."
Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease, according to a new study by rheumatology researchers at Hospital for Special Surgery. The study appears online ahead of print, in the journal Arthritis and Rheumatism.
The Biomarker Discovery Center at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine has been awarded a three-year, $799,800 grant from the Osteopathic Heritage Foundation to develop a blood test that can diagnose mild cognitive impairment (MCI) caused by early-stage Alzheimer's disease.
Their study titled, "Religious affiliation and the risk of COVID 19 related mortality; a retrospective analysis of variation in pre and post lockdown risk by religious group in England and Wales," was published in the pre-publication site medRxiv.
Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.
› Verified 5 days ago
| Entity Name | Mercer Allergy & Pulmonary Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073936399 PECOS PAC ID: 9436376605 Enrollment ID: O20140812000860 |
News Archive
Connecticut: The Associated Press/Hartford Courant reports, "Gov. M. Jodi Rell has vetoed two health insurance bills he said were "well-intentioned" but "would cost the state billions of dollars before any economic recovery is complete."
Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease, according to a new study by rheumatology researchers at Hospital for Special Surgery. The study appears online ahead of print, in the journal Arthritis and Rheumatism.
The Biomarker Discovery Center at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine has been awarded a three-year, $799,800 grant from the Osteopathic Heritage Foundation to develop a blood test that can diagnose mild cognitive impairment (MCI) caused by early-stage Alzheimer's disease.
Their study titled, "Religious affiliation and the risk of COVID 19 related mortality; a retrospective analysis of variation in pre and post lockdown risk by religious group in England and Wales," was published in the pre-publication site medRxiv.
Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.
› Verified 5 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Peter Anthony Ricketti, DO 1544 Kuser Rd Ste C6, Trenton, NJ 08619-3830 Ph: (609) 581-9900 | Dr Peter Anthony Ricketti, DO 1544 Kuser Rd Ste C6, Trenton, NJ 08619-3830 Ph: (609) 581-9900 |
News Archive
Connecticut: The Associated Press/Hartford Courant reports, "Gov. M. Jodi Rell has vetoed two health insurance bills he said were "well-intentioned" but "would cost the state billions of dollars before any economic recovery is complete."
Rituximab, a drug used to treat cancer and arthritis, may help patients with antiphospholipid antibodies (aPLs) who suffer from aPL-related clinical problems that do not respond to anticoagulation, such as cardiac disease and kidney disease, according to a new study by rheumatology researchers at Hospital for Special Surgery. The study appears online ahead of print, in the journal Arthritis and Rheumatism.
The Biomarker Discovery Center at the University of Medicine and Dentistry of New Jersey-School of Osteopathic Medicine has been awarded a three-year, $799,800 grant from the Osteopathic Heritage Foundation to develop a blood test that can diagnose mild cognitive impairment (MCI) caused by early-stage Alzheimer's disease.
Their study titled, "Religious affiliation and the risk of COVID 19 related mortality; a retrospective analysis of variation in pre and post lockdown risk by religious group in England and Wales," was published in the pre-publication site medRxiv.
Merck reported today that final results from two pivotal Phase III studies of boceprevir, its investigational oral hepatitis C protease inhibitor, demonstrated significantly higher sustained virologic response (SVR) rates in adult patients who previously failed treatment (treatment-failure; HCV RESPOND-2) and in adult patients who were new to treatment for chronic hepatitis C virus (HCV) genotype 1 compared to control, the primary objective of the studies.
› Verified 5 days ago
Dr. Abdul W Mughal, M.D. Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 40 Fuld St, Suite 404, Trenton, NJ 08638 Phone: 609-394-0660 Fax: 609-394-1004 | |
Delaram Moazami, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 750 Brunswick Ave, Trenton, NJ 08638 Phone: 609-394-6000 | |
Deepika Suleria, Internal Medicine Medicare: Medicare Enrolled Practice Location: 750 Brunswick Ave, Trenton, NJ 08638 Phone: 609-394-6031 | |
Dr. Khadija Baig, MD Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 750 Brunswick Ave, Trenton, NJ 08638 Phone: 609-394-6000 | |
Christine Marie Capio, MD Internal Medicine Medicare: Medicare Enrolled Practice Location: 132 Perry St, Trenton, NJ 08618 Phone: 609-394-8988 Fax: 609-394-8842 | |
Robert Eugene Colella, DO Internal Medicine Medicare: Accepting Medicare Assignments Practice Location: 601 Hamilton Ave, Trenton, NJ 08629 Phone: 609-599-5000 |